Black Diamond director takes 7,907 shares as fees

Rhea-AI Filing Summary

Raman Prakash reported acquisition or exercise transactions in this Form 4 filing.

Black Diamond Therapeutics director Raman Prakash received 7,907 shares of common stock as equity compensation. The shares were granted in lieu of cash fees under the company’s Sixth Amended and Restated Non-Employee Director Compensation Policy at a reference price of $1.66 per share, based on the June 18, 2026 closing price. Following this award, Prakash directly holds 45,039 shares.

Insights

Equity compensation analyst

Director received routine equity compensation instead of cash fees.

Director Raman Prakash was granted 7,907 shares of Black Diamond Therapeutics common stock as a compensation award, valued using the $1.66 closing price on June 18, 2026. This reflects a non-cash form of annual director fees.

The transaction is categorized as a grant/award acquisition rather than an open-market purchase or sale, so it carries limited signaling value about the director’s view of the stock. After the award, Prakash directly owns 45,039 shares, indicating a modest ongoing equity stake.

Insider Trade Summary

Net Buyer: 7,907 shares

Net Buy 1 txn

Insider Raman Prakash

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	7,907	$1.66	$13K

Holdings After Transaction: Common Stock — 45,039 shares (Direct)

Footnotes (2)

1. F1. These shares were issued in accordance with the Issuer's Sixth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer.
2. F2. The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on June 18, 2026.

Key Figures

Director share grant: 7,907 shares Reference share price: $1.66 per share Post-transaction holdings: 45,039 shares

3 metrics

Director share grant 7,907 shares Common stock award on June 19, 2026

Reference share price $1.66 per share Closing price on June 18, 2026 used for grant valuation

Post-transaction holdings 45,039 shares Director’s direct ownership after the grant

Key Terms

Non-Employee Director Compensation Policy, grant, award, or other acquisition, closing market price

3 terms

Non-Employee Director Compensation Policy financial

"issued in accordance with the Issuer's Sixth Amended and Restated Non-Employee Director Compensation Policy"

grant, award, or other acquisition financial

"transaction code A described as Grant, award, or other acquisition"

closing market price financial

"price is based upon the closing market price of the Issuer's common stock"

FAQ

What did Black Diamond Therapeutics (BDTX) director Raman Prakash report in this Form 4?

Director Raman Prakash reported receiving 7,907 shares of Black Diamond Therapeutics common stock. The shares were granted as compensation under the company’s non-employee director policy, increasing his direct holdings to 45,039 shares after the transaction.

Was the Black Diamond Therapeutics (BDTX) Form 4 transaction a market purchase or sale?

The transaction was a grant or award, not a market purchase or sale. Shares were issued as compensation in lieu of cash fees, so no open-market buying or selling occurred in connection with this Form 4 filing.

At what price was the Black Diamond Therapeutics (BDTX) director share grant valued?

The 7,907-share grant to director Raman Prakash was valued using a reference price of $1.66 per share. This price reflects the closing market price of Black Diamond Therapeutics common stock on June 18, 2026, as noted in the filing footnote.

How many Black Diamond Therapeutics (BDTX) shares does director Raman Prakash own after this grant?

After receiving 7,907 shares as compensation, director Raman Prakash directly owns 45,039 shares of Black Diamond Therapeutics common stock. This total reflects his position immediately following the reported Form 4 transaction on June 19, 2026.

Why did Black Diamond Therapeutics (BDTX) issue shares to the director instead of paying cash?

Shares were issued under the company’s Sixth Amended and Restated Non-Employee Director Compensation Policy. This policy allowed Raman Prakash to elect to receive common stock instead of cash compensation for his annual services as a non-employee director.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/22/2026 - 04:06 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Raman Prakash

(Last) (First) (Middle)

C/O BLACK DIAMOND THERAPEUTICS, INC.

245 FIRST STREET, 18TH FLOOR

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Black Diamond Therapeutics, Inc. [ BDTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/19/2026		A(1)		7,907	A	$1.66(2)	45,039	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares were issued in accordance with the Issuer's Sixth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer.

2. The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on June 18, 2026.

	/s/ Brent Hatzis-Schoch, Attorney-in-Fact	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)